Eli Lilly collaborates with the Trump administration to improve access to GLP-1 receptor agonists for millions of Americans, including those on government programs. The agreement allows Medicare ...

Pharma’s push into direct-to-patient sales is reshaping the front end of drug distribution, but wholesalers like Cencora, McKesson, and Cardinal Health remain indispensable as the backbone of the ...

Starjemza's inclusion in Cost Plus Drugs' portfolio aims to challenge traditional specialty medication economics and enhance ...

Ho next-generation AI-driven traceability hubs can transform pharmaceutical serialization from a compliance requirement into a business advantage, while enabling real-time supply chain visibility, ...

Ultimately, Khan emphasized that protecting PHI requires more than compliance checkboxes—it demands a continuous, structured ...

By partnering with Surescripts, life sciences companies can tap into a vast network of health plans and pharmacy benefit ...

In the world of CGT products, change is the only constant. Whether it be new regulations, shifting reimbursement models, or evolving patient needs, a flexible channel strategy is table stakes and a ...

The formula for bridging scientific advancement with operational flexibility in boosting access to cell and gene therapies.

Eli Lilly's new facility in the Netherlands will enhance European manufacturing capacity and global supply chain efficiency. The facility will produce oral solid medicines and orforglipron, a GLP-1 ...